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ABSTRACT
MASTL (microtubule-associated serine/threonine kinase-like), more commonly 
known as Greatwall (GWL), has been proposed as a novel cancer therapy target. GWL 
plays a crucial role in mitotic progression, via its known substrates ENSA/ARPP19, 
which when phosphorylated inactivate PP2A/B55 phosphatase. When over-expressed 
in breast cancer, GWL induces oncogenic properties such as transformation and 
invasiveness. Conversely, down-regulation of GWL selectively sensitises tumour cells 
to chemotherapy. Here we describe the first structure of the GWL minimal kinase 
domain and development of a small-molecule inhibitor GKI-1 (Greatwall Kinase 
Inhibitor-1). In vitro, GKI-1 inhibits full-length human GWL, and shows cellular 
efficacy. Treatment of HeLa cells with GKI-1 reduces ENSA/ARPP19 phosphorylation 
levels, such that they are comparable to those obtained by siRNA depletion of GWL; 
resulting in a decrease in mitotic events, mitotic arrest/cell death and cytokinesis 
failure. Furthermore, GKI-1 will be a useful starting point for the development of more 
potent and selective GWL inhibitors.
INTRODUCTION
The mitotic kinase MASTL (microtubule-associated 
serine/threonine kinase-like) - more commonly known as 
Greatwall kinase or GWL - belongs to the AGC family of 
serine/threonine protein kinases and has recently emerged 
as a potential target for cancer chemoprevention [1-5]. 
GWL exerts its biological activity by phosphorylating 
α-endosulfine (ENSA) and/or cAMP-regulated 
phosphoprotein 19 (ARPP19). Once phosphorylated, 
these proteins become potent inhibitors of the protein 
phosphatase 2A complex (PP2A/B55) [6, 7]. PP2A/B55 
counteracts CDK1 during mitosis by dephosphorylating 
mitotic CDK1 substrates. Negative regulation of PP2A/
B55 by GWL thus results in a positive feedback loop that 
boosts CDK1 activity above the threshold required for 
mitotic entry. In addition to its mitotic roles, GWL also 
contributes to AKT activation by negatively regulating 
the AKT phosphatase PHLPP [5]. Moreover, studies from 
both budding and fission yeast have also implicated the 
GWL/ENSA pathway in linking metabolic responses to 
cell cycle control [8-10].
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Mutation of GWL in Drosophila causes defects in 
chromosomal condensation, as well as delayed mitotic 
entry and exit in neuroblasts [11]. Studies in Xenopus 
extracts also showed that GWL plays an important role 
in mitotic entry and in DNA-damage checkpoint recovery 
in late G2-phase [12-14]. Likewise, depletion of the 
mammalian orthologue of GWL by siRNA in human 
cells, or by Cre-mediated excision in mouse embryonic 
fibroblasts, causes severe mitotic phenotypes such as 
aneuploidy, defects in chromosome condensation and 
failure to inactivate the spindle assembly checkpoint, 
with consequent defects in chromosome segregation and 
cytokinesis [1, 15-17].
Non-transformed cell lines, such as HaCaT and 
OKF4, have been found to have significantly lower 
levels of GWL protein when compared to some cancer-
derived cells lines [4]. Accordingly, levels of GWL are 
seen to be elevated in oral squamous cell carcinoma, 
breast cancer and prostate cancer tissues [5]. Taken 
together these findings suggest that GWL may have an 
adaptive role in some cancer types, and may contribute 
directly to tumourigenesis. This could potentially be 
due to the non-mitotic functions of GWL, such as the 
regulation of AKT activity, but the precise role of GWL 
in cellular transformation remains largely unexplored. 
Thus, pharmacologic targeting of GWL could be a useful 
tool for analysing these tumour-associated functions and 
may ultimately prove to be a clinically useful strategy for 
targeting specific sub-classes of tumours.
To date, no X-ray structures of GWL are available. 
Although highly related at the amino acid sequence level 
to the N- and C-terminal kinase lobes of the MAST 
kinases (microtubule-associated serine/threonine kinase; 
MAST1, 2, 3 and 4) and other AGC kinases, GWL has 
a highly unusual architecture, with an ~500 amino 
acid insertion between the DFG and APE motifs of the 
activation segment connecting the N- and C-terminal lobes 
(NCMR; non-conserved middle region). The structure and 
function of the NCMR, which is less well conserved than 
the encompassing kinase domain, remains enigmatic, but 
appears to be dispensable, at least in part, for its biological 
function [18].
In pursuit of developing human GWL as a target for 
drug discovery we have developed a minimal GWL kinase 
domain construct, in which the NCMR has been deleted 
and a conventional AGC-kinase activation segment 
inserted in its place. This construct is soluble even when 
purified from E.coli, and displays specific kinase activity 
towards its bona fide substrate ENSA. We have determined 
the X-ray crystal structure of this construct and have 
developed a first generation inhibitor displaying in cellulo 
efficacy, based on a small-scale inhibitor screen and 
rational SAR-driven design. This molecule, GKI-1, may 
find utility as a lead / tool compound to inform the on-
going development of potent and specific GWL inhibitors.
RESULTS
Construct design, expression and purification
We found that recombinant full-length human GWL 
(hGWLFL) containing the entire NCMR insert (Figure 
1A, Top) did not express in a soluble form in Escherichia 
coli. Although amenable to expression in Spodoptera 
frugipera cells using recombinant baculovirus, the overall 
yields were low (our own unpublished observations). We 
therefore sought an alternative strategy to produce enough 
protein to facilitate both structural and functional studies, 
as well as to support our drug discovery efforts.
Through bioinformatic analysis, we noted that the 
amino acid sequence preceding the conserved ‘APE’ 
kinase motif of hGWL resembled that of the PKC (Protein 
Kinase C) family of kinases, in particular the alpha 
isozyme [19] (Figure 1A, Bottom). We therefore excised 
the NCMR of hGWL and replaced it with four amino 
acids 496 - RTFC - 499 taken from human PKCα, to 
generate the expression construct ‘hGWL-KinDom’ (see 
Experimental Section).
The resultant fusion was readily expressed in, and 
then purified from E.coli, using standard chromatographic 
procedures (see Supporting Information). The GST-
hGWL-KinDom fusion co-purified with the E.coli 
chaperone GroEL, but could be efficiently released by 
incubation with ATP [20] and the affinity tag removed, 
to give pure soluble hGWL-KinDom (Supporting 
Information, Figure S1).
Enzyme characterisation
Firstly, we examined the phosphorylation status 
of purified hGWL-KinDom by mass spectrometry. 
We could identify peptides, obtained from protease 
digests, which corresponded to phosphorylation at 
amino acids Thr17, Thr868, Thr873, Ser875 and Ser878 
(Supporting Information, Figure S2). Experiments with 
immunoprecipitated full-length GWL (human or Xenopus), 
as well as several independent proteomic screens, have 
documented both Ser875 and Ser878 phosphorylation 
sites [18, 21-24]. The three remaining sites are therefore 
likely to be unique to hGWL-KinDom and arise as a direct 
consequence of its heterologous expression in E.coli; an 
observation consistent with other human protein kinases 
[25]. Arguably however, only phosphorylation at Ser875 
is functionally relevant - the S875A mutation severely 
compromises GWL kinase activity, whereas the S878A 
mutation does not [18, 24]. Mutation of Ser875 also 
prevents the timely reactivation of PP2A activity in order 
to complete mitosis [26].
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Figure 1: Biochemical and biophysical characterisation of the minimal kinase construct hGWL-KinDom. (A., top) GWL 
is an unusual bifurcated protein kinase, containing a large ~500 amino acid insertion (NCMR, non-conserved middle region) between 
the conserved DFG and APE motifs of the activation segment / T-loop. The amino acid boundaries of the N- and C-lobes of the kinase 
domain are indicated, as well as the C-terminal phosphorylation site (Ser875) known to be essential for function. (A., bottom) Amino acid 
sequence alignment of the activation segment / T-loop of human GWL with the PKC isoforms alpha (α) and iota (ι). Threonine residues 
within this region of GWL are known to be phosphorylated in vivo, Thr194 by Cdk1 [28] and the equivalent of Thr718 in Xenopus laevis 
GWL (T725) [24]. The equivalent residues in PKC-α and PCKι, Thr497 and Thr412 respectively, are instead phosphorylated by PDK1. 
The ‘RTFC’ sequence taken from PKCα, in order to generate hGWL-KinDom is highlighted. Absolutely conserved residues are shown 
with a black background, with residues conserved by property shown with a grey background. B. hGWL-KinDom was serially diluted by 
2-fold and each concentration was subjected to a radioactive kinase assay. The same concentrations of hGWL-KinDom were analysed by 
western analysis. Immunoprecipitated Flag-tagged hGWLFL was subjected to the same analyses as assay controls. C. Kinase activity was 
normalised to total ENSA levels, measured as the 32P-Ensa intensity (autorad)/ENSA intensity (densitometry) ratio and plotted as fold-
induction relative to background; kinase deficient control reaction. (D,E) Kinetic parameters (kcat, KM) were established by diluting either 
ATP or ENSA serially by 2-fold and subjecting each concentration to a Kinase-Glo Max assay. Non-linear regression using Prism 6.0 and 
the built-in enzyme kinetics module were used to determine Michaelis-Menten kinetic parameters, kcat and Km, for both ATP D. and ENSA 
E. F. hGWL-KinDom was subjected to either increasing concentrations of staurosporine (STU) or DMSO and the resulting kinase activity 
was determined using the Kinase-Glo Max assay. The % kinase activity was normalised to the DMSO control and non-linear regression 
using Prism 6.0 was used to determine IC50 values. G.Thermal shift assay. Binding of hGWL-KinDom (1.5 μM) to STU (10μM) produces 
a positive temperature mid-point (Tm) shift of 8.2 °C, indicating compound binding.
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We next sought to test if hGWL-KinDom 
phosphorylated the known GWL substrate ENSA [6, 
7, 27]. To this end, we used an in vitro kinase reaction 
with radiolabelled ATP (g-32P) to directly visualise 
phosphorylated ENSA by autoradiography (Figure 1B) 
and then to quantitate activity using photo-stimulated 
luminescence (Figure 1C). The enzyme readily 
phosphorylated ENSA, and at high concentrations reached 
saturation. Flag-tagged hGWLFL immunoprecipitated 
from human cells was used as an assay control [28] and 
displayed only slightly greater activity when compared to 
the equivalent concentration of hGWL-KinDom (25 nM; 
Figure 1B and 1C).
Secondly, using a commercial luminescence-based 
assay (Kinase-Glo Max, Promega), we were subsequently 
able to measure enzymatic parameters for hGWL-KinDom 
determining Km and kcat values of 17.2 ± 2.4 μM and 10.4 ± 
0.48 s-1 for ATP hydrolysis, and Km and kcat values of 1.6 ± 
0.3 μM and 0.2 ± 0.01 s-1 for ENSA as a substrate (Figure 
1D and 1E).
We next tested if the pan-kinase inhibitor 
staurosporine (STU) affected hGWL-KinDom catalytic 
activity by incubating fixed concentrations of the enzyme, 
ENSA and ATP with increasing concentrations of the 
inhibitor, and then assaying for ATP turnover in the 
same luminescence-based format. STU clearly inhibited 
kinase activity, with an IC50 of ~ 9 µM (Figure 1F). We 
additionally confirmed binding of STU to hGWL-KinDom 
by thermal shift assay [29] (Figure 1G), producing a robust 
temperature midpoint shift (ΔTm) of 8.2 °C under the 
experimental conditions tested (Supporting Information).
Crystal structure of hGWL-KinDom in complex 
with staurosporine
Diffracting crystals of hGWL-KinDom in complex 
with STU were obtained from commercially available 
screens. The structure was determined by molecular 
replacement, and refined at a resolution of 3.1Å (see 
Supporting Information, Figure S3 and Table S1 for 
crystallographic and refinement data). As expected, 
hGWL-KinDom adopts the classical ‘two-lobe’ protein 
kinase domain fold [30] (Figure 2A). As both the C-helix 
and activation loop regions are disordered in electron 
density maps, this strongly suggests that just the non-
phosphorylated form of hGWL-KinDom (in complex with 
STU) was selectively incorporated into protein crystals.
As expected, STU occupies the nucleotide-binding 
pocket, making hydrogen bonds to the backbone carbonyl 
and nitrogen of hinge residues Glu111 and Leu113, 
via its lactam nitrogen (N6) and oxygen (O6) groups, 
respectively (nomenclature as described in [31]). It is 
also ‘sandwiched’ on both sides, by several hydrophobic 
residues, including Ile41, Val49, Ala60 and Leu163 from 
the N-lobe, and Thr173 and Leu163 from the C-lobe 
(Figure 2B).
The C-terminal extension of hGWL-KinDom
A homology model for the kinase domain of 
hGWL was previously reported by Vigneron et al. [24], 
which they used to determine if conserved motifs of the 
‘C-terminal extension’ - found in many AGC-family 
protein kinases - were also present in GWL (Figure 2C, 
top; reviewed by [30, 32, 33]); their analyses confirmed 
the presence of AGC-insert, C-lobe anchor (CLA), C-lobe 
tether (CLT) and active-site tether (AST) motifs, and 
absence of the N-lobe tether (NLT) and hydrophobic (HM) 
motifs.
In electron density maps, we can observe amino 
acids 825-854 of the GWL C-terminal extension, 
containing both the C-lobe anchor (CLA) and the 
majority of the C-lobe tether (CLT) motifs (Figure 2C, 
bottom). However, the active-site tether (AST) region at 
the extreme C-terminus of hGWL-KinDom is not visible 
(aa 855-879) despite being encoded in the expression 
construct.
As in other AGC-kinases [30, 32, 33], such as PDK1 
[34] and PKCα [35], the GWL C-terminal extension wraps 
across one face of the C-lobe, making an extensive series 
of predominantly hydrophobic interactions. A highly 
conserved aromatic side chain Trp840 and a subsequent 
hydrophobic residue Leu843, both situated within the CLA 
and immediately preceding the PXXP motif (849-PFIP-
852), serve to anchor the extended C-terminal region to the 
body of the kinase domain (Figure 2C, top and bottom). 
Mutation of residues within either motif, when introduced 
into full-length hGWL results in markedly reduced levels 
of kinase activity (W840A = 57% reduction, P849A / 
P852A = 90% reduction; [24]) confirming their relevance 
and importance to the normal cellular functions of GWL.
Vigneron et al., also indicated that GWL contains 
both a functional tail / linker binding pocket, and a 
hydrophobic-motif binding pocket within its N-lobe, 
which we confirm and corroborate with our structural data. 
The side-chains of Lys48 (N-lobe) and Lys65 (C-helix) 
would be suitably positioned to interact with the Ser875 
phosphorylation site (AST motif) that is critical for GWL 
function, as indicated by structural superimposition of the 
C-terminal extension of PKC βII onto hGWL-KinDom 
(PDB: 2I0E; Figure 2D). Likewise, a canonical HM from 
another protein kinase [F-x-x-F-(S/T/D)-Y/F] could be 
readily accommodated by a pocket lined by the side-
chains of Met69, Ser99, Val106 and Leu108 of the N-lobe, 
plus Gln79 and Arg82 of the C-helix (Figure 2E).
Pharmacological classification of hGWL-KinDom
With both biochemical and structural validation 
of our minimal kinase domain, we next sought to 
pharmacologically characterise hGWL-KinDom, to 
address its suitability for screens that looked to identify 
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Figure 2: X-ray crystal structure of hGWL-KinDom in complex with STU. A. Secondary structure molecular cartoon. The 
components of the kinase domain are coloured according to [30]. Staurosporine (STU) is shown in stick representation, with carbon atoms 
coloured in green. Please see associated key for further details. B. Molecular details for STU bound to hGWL-KinDom. Selected amino acids 
are shown in stick representation (labelled), with carbon atoms coloured in grey. The carbon atoms of STU are coloured in green. Orange 
dotted-lines indicate potential hydrogen-bonds made between the protein and STU. (C., Top) Amino acid sequence for the C-terminal 
region of GWL (amino acids 825-869), highlighting the C-lobe anchor (CLA), C-lobe tether (CLT) and active-site tether (AST) regions; as 
described in [24]. The positions of Trp840 and Leu843, residues which when mutated affect GWL kinase activity, are indicated (arrows). 
Phosphorylation sites, unique to the AST of hGWL-KinDom when expressed in E.coli, are indicated by red coloured circles. Sites common 
to both hGWLFL and hGWL-KinDom are indicated by cyan coloured circles. (C., Bottom) Molecular details for the CLA/CLT region 
of hGWL-KinDom. Amino acids of the CLA/CLT regions (coloured in pink) make a series of predominantly hydrophobic interactions 
with the C-lobe of the kinase domain (coloured yellow). The identity of key amino acid residues are indicated (stick representation). The 
positions of Trp840 and Leu843 are additionally highlighted (arrows). D. Molecular details for the phospho-binding pocket of GWL. Using 
the X-ray crystal structure of the PKCβ  II kinase domain as a reference (PDB: 2I0E), it is possible to determine that amino acids Lys48, 
Lys65 and Tyr107 (stick representation) are positioned such that they could interact with the phosphorylated AST of GWL (pSer875). E. 
Molecular details for the Hydrophobic Motif-binding pocket. The side chains of amino acids Lys66, Met69, Gln79, Arg82, Ala86, Leu90, 
Leu108, and Phe659 (stick representation) form a potential hydrophobic motif-binding pocket in the N-lobe of GWL. Please see associated 
key for additional details. Note, in Figures D and E, the C-lobe of hGWL has been homology-modelled (carbons coloured in orange).
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inhibitors of the full-length human enzyme.
Using the same luminescence-based kinase assay, 
we determined IC50 values for inhibition of both hGWL-
KinDom and immunoprecipitated hGWLFL kinase 
activity by STU; 9.1 and 3.1 µM respectively (Figures 
1F and Supporting Information, Figure S4A and C). This 
reasonable level of agreement between values (an ~3-
fold difference) indicates that STU has similar affinities 
for both the minimal kinase domain and its full-length 
counterpart.
We next demonstrated that the known AGC 
kinase inhibitor AT13148 inhibited hGWL-KinDom, 
determining an IC50 of 125 ± 1.7 nM; a value similar to 
those determined for other AGC kinases inhibited by this 
compound [36] (Figure 3). Interestingly, when tested on 
hGWLFL we determined that the IC50 values of AT13148 
and STU are nearly equipotent at hGWLFL inhibition 
(AT13148 IC50/STU IC50 = ~ 2) (Figure 3 and Supporting 
Information, Figure S4B and D). Together these data 
suggest that, despite the complete excision of the NCMR 
insertion, hGWL-KinDom retains several important 
structural features specific to hGWLFL (and other AGC 
kinases) in and around its ATP-binding pocket. With this 
validation of our experimental approach, we decided to 
use hGWL-KinDom in screens as part of our discovery 
efforts to identify inhibitors of GWL kinase activity.
Structure-activity relationship analysis of ‘hits’
Select compounds, ranking amongst the 8 most 
potent, identified in a high-throughput screen of a 
small-molecule library enriched for protein kinase 
inhibitors (Supporting Information, Figure S5) were 
taken forward into a second, confirmatory screen, using 
immunoprecipitated hGWLFL as the enzyme (Supporting 
Information, Figure S6). Interestingly, GRI-3 and GRI-4 
produced IC50 values with a good level of agreement to 
those previously obtained for hGWL-KinDom (Table 1, 
Supporting Information, Figures S6 and S7). However, 
both GRI-1 and -2, did not demonstrably inhibit the full-
length enzyme (Table 1, Supporting Information, Figure 
S6A and B). We also found a similar disagreement in IC50 
using the AGC kinase inhibitor AT13148; inhibitory ratio 
= 45, (IC50 hGWLFL /IC50 hGWL-KinDom) (Figure 3).
A common feature of AT13148, GRI-1 and -2 is that 
they contain branching groups that are connected to either 
a bridging quaternary carbon (AT13148) or that protrude 
toward, and are situated directly above the bridging 
methine linking group (GRI-1 and -2, Figures 3 and 4A). 
Compounds GRI-3 and -4, whilst showing structural 
similarity to the AT13148 inhibitor, lack this substitution 
pattern around their aniline and ketone linkers (Table 1 
and Figure 4A).
Figure 3: Pharmacologic analysis of hGWL-KinDom and hGWLFL with the AGC kinase inhibitor AT13148. hGWL-
KinDom () or immunoprecipitated hGWLFL (☐) was treated with increasing concentrations of AT13148 and kinase activity was measured 
by either the Kinase-Glo Max () or immunoprecipitation kinase assays (☐). Non-linear regression with Prism 6.0 was used to determine 
IC50 values.
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Superposition of PKA-PKB chimera in complex 
with AT13148 (PDB: 4AXA) onto hGWL-KinDom 
(where the disordered C-helix was modelled by sequence-
threading [37]) revealed a large, solvent-exposed pocket 
proximal to the ATP / inhibitor-binding site (Figure 4B). 
In the minimal kinase domain, this pocket may facilitate 
binding of all the compounds, whereas in the full-length 
protein, where the NCMR is likely to occupy (some or 
all of) this space, GRI-1, -2 and AT13148, would be 
prevented from binding through steric hindrance (Figure 
4B and 4C).
To test this hypothesis, we synthesised the ‘hybrid-
compounds’ GKI-1 and -2, where we eliminated both the 
alcohol and methylamine groups of AT13148, and replaced 
the carbon linker with an aniline linker, to theoretically 
remove the chemical elements that correlated negatively 
with inhibition of full-length GWL (Figure 4D, Supporting 
Information, Figure S8A, Scheme 1). Interestingly, whilst 
molecular docking studies indicated that both compounds 
should have similar binding energies (-7.4 to -7.9 kcal/
mol; Supporting Information, Figure S8A and B), GKI-
2 did not demonstrably inhibit hGWLFL (Supporting 
Information, Figure S8C and D). It was therefore not 
taken forward into cellular assays. In contrast, the EC50 
Table 1: Secondary screening of select compounds from the inhibitor screen was performed using Flag-tagged hGWLFL 
and hGWL-KinDom in the immunoprecipitation and Kinase-Glo Max kinase assays. 
Structure Compound Rank % Inhibition1 IC50 (µM)2 IC50 (µM)3
GRI-1 1 67.6 >100 N.D.
GRI-2 5 37.0 >100 N.D.
GRI-3* 3 39.6 66 109 ± 13.7
GRI-4** 8 30.1 2.5 3.22 ± 0.31
IC50 values were measured for GRI-1, -2, -3 and -4.1Screening Data, ATP concentration = 45 µM, 2GWLFL, 3GWL-KinDom, 
*(IC50 GWLFL/IC50 GWL-KinDom) = 0.6, **(IC50 GWLFL/IC50 GWL-KinDom) = 0.8
Scheme 1: Synthesis of GKI-1/2.
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and IC50 values obtained for GKI-1 against both hGWLFL 
and hGWL-KinDom were found to be highly similar (4.9 
and 2.5 µM respectively, inhibitory ratio = ~ 2; Figure 4E 
and 4F).
We also tested GKI-1 against CDK2 (IC50 value of 
89.0 ± 2.7 nM, Table 2), as we believed it would have 
increased specificity towards GWL, over the parent 
compound GRI-4; a potent CDK inhibitor [38]. As 
predicted, GKI-1 had no observable inhibitory activity 
towards CDK2 at concentrations up to 100 μM (Table 
2). The X-ray crystal structure of CDK2 in complex 
with a GRI-4 related compound, indicates that an 
anilinopyrimidine constituent is important for compound 
binding, as it participates in hydrogen-bonding interactions 
with the hinge region (PDB: 3EID [38]). We believe, 
therefore, that the lack of CDK2 inhibitory activity is due 
to the absence of this group in GKI-1.
Selectivity profiling of GKI-1
To determine whether GKI-1 had any level of 
selectivity towards kinases within the AGC-family, we 
examined its effect on the activities of two commercially 
available proteins, ROCK1 and PKA; selected as they 
are known to be potently inhibited by the AGC kinase 
inhibitor AT13148, with experimentally determined IC50 
values of ~6 and 11 nM respectively [36] (Table 2).
GKI-1 robustly inhibited ROCK1 with an IC50 
of ~11 µM, but only weakly affected PKA; IC50 > 40 
µM (Table 2). The bioinformatics tool Kinase SARfari 
(EMBL-EBI) enabled us to rationalise these data, as it 
indicates that the active site of ROCK1 (at the amino acid 
sequence level) is more similar to that of hGWL (distance 
score = 0.85; Supporting Information, Table S2) than 
those of the PKA isoforms (score = 1.85), thus providing 
a simple explanation for the apparent selectivity profile of 
GKI-1 [39]; 2-fold selectivity for binding to hGWLFL over 
ROCK1, but greater than 8-fold selectivity over PKA.
In order to gain a greater understanding of potential 
off-target interactions of GKI-1, we undertook more 
rigorous kinase inhibition profiling (International Centre 
for Kinase Profiling, University of Dundee) where GKI-1 
was tested against 50 different protein kinases, carefully 
selected to provide representative sampling across the 
human kinome. At the 25 µM concentration tested, GKI-
1 clearly has several off-target interactions, but they are 
particularly focussed around the AGC kinase family 
(Supporting Information Figure S9).
In cellulo efficacy of GKI-1
To more directly address the presence of other off-
target effects, and / or any level of compound toxicity, we 
conducted a more comprehensive phenotypic analysis 
of GKI-1 and GWL siRNA (siGWL, Figure 5A) treated 
cells by immunofluorescence (IF) and time-lapse video 
microscopy. Using an antibody that specifically detects 
phosphorylation of ENSA-Ser67 (p-ENSA) [28], we 
established an IF assay in order to measure GWL kinase 
activity in HeLa cells. We treated the cells with nocodazole 
in order to arrest cells in mitosis, the cell cycle stage where 
GWL is maximally active [16] (Figure 5B).
Co-incubation of HeLa cells with nocodazole 
and GKI-1 resulted in a dose-dependent decrease in the 
levels of p-ENSA as judged by immunofluorescence; 
an effect mirrored by siRNA depletion of GWL (Figure 
5B). Quantitation indicated a 2-fold reduction in p-ENSA 
levels, compared to control, when cells were treated with 
25 μM GKI-1. A concentration of 50 μM GKI-1 further 
reduced the p-ENSA signal to levels comparable to siGWL 
treated cells (Figure 5C).
The hallmark phenotypes of GWL depletion in 
mammalian cells are a delay in mitotic entry, prolonged 
prometaphase arrest and mitotic exit with aberrant 
cytokinesis [15, 16]. To test if our compound elicits similar 
phenotypes we performed live cell imaging of HeLa cells 
Table 2: Specificity profile of GKI-1. 
AT13148 GRI-4 GKI-1
Kinase IC50 (µM  ± S.D.)
PKA 0.00613 ± 0.002 >100 >40
ROCK1 0.0114 ± 0.004 21.6 ± 5.3 11.3 ± 3.4
CDK2 N.D. 0.0890 ± 0.003 >100
AT13148, GRI-4 and GKI-1 were tested against PKA, ROCK1 and CDK2 using the Kinase-Glo Max and immunoprecipitation 
kinase assays.
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Figure 4: Model describing the minimal structural requirements for small-molecule inhibition of hGWLFL. A. Small 
molecule inhibitors are rendered as a green or green and orange cartoons with (orange appendage) or without the alkynyl appendage. B. 
GWL is rendered as a cartoon with (hGWLFL) or without (hGWL-KinDom) the NCMR region. This model illustrates how the NCMR 
could act as a steric filter, which prevents small-molecules with large appendages from docking within the nucleotide-binding site. C. 
Molecular modelling of AT13148 within the nucleotide-binding site of hGWL. Docking with hGWL-KinDom crystal structure (where 
the disordered C-helix was homology-modelled) reveals a large solvent-exposed pocket vicinal to the ligand-binding site. D. Rational 
design of a first generation hGWL inhibitor using an AT13148 scaffold and incorporating the GRI-4 aniline linker. E., F. hGWL-KinDom 
() or immunoprecipitated hGWLFL () were treated with increasing concentrations of GKI-1 and kinase activity was measured by either 
the Kinase-Glo Max (☐) or immunoprecipitation kinase assays (☐). (F) % kinase activity was normalised to the DMSO control, and the 
smallest and largest values defined and plotted as 0 and 100 % kinase activity respectively. Non-linear regression with Prism 6.0 was used 
to determine IC50 (hGWL-KinDom) or EC50 (hGWLFL) values.
Oncotarget10www.impactjournals.com/oncotarget
Figure 5: In cellulo efficacy of GKI-1 in HeLa cells. A. HeLa cells were transfected with either non-targeting (siSCR) or GWL 
targeting siRNAs (siGWL). GWL and loading control protein (Tubulin) were detected by western analysis. B., C. HeLa cells treated with 
siSCR or siGWL (48-h) were arrested in mitosis using nocodazole and treated with DMSO, 25 µM or 50 µM GKI-1. Immunofluorescent 
staining of p-ENSA (Red) and GWL (Green) was achieved using anti-phospho(Ser67)-ENSA and anti-MASTL(GWL, RIPLY 74C) 
antibodies and DAPI was used to stain the nucleus (Blue). (C) Quantitation of the IF p-ENSA and GWL signals was performed using the 
ScanR High-Content Screening Station. The Circularity and Total DAPI parameters were used to identify mitotic cells. D., E. HeLa cells 
treated with siSCR or siGWL (48-h) were treated with DMSO, 25 or 50 µM GKI-1. 4-h after treatment, µ-slides were mounted onto an 
Olympus IX73 microscope, within a temperature-controlled 370 C chamber maintained at 5% CO2, and images were acquired every 5-min 
for 8.5-h. Time-lapse videos were generated using ImageJ and cellular phenotypes recorded: Mitotic events (D), mitotic arrest (E, F) and 
failed cytokinesis G. F. Kymographs showing an example of typical phenotypes were generated by capturing images every 5 minutes for 
80 minutes. Image sequences were chosen to start just before mitotic entry. (B - G) A total of 3 - 5 biological replicates were completed 
per condition and the t-test statistical module of Prism 6.0 was used to determine p-values (ns (not statistically significant): P > 0.05; *: P 
≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001).
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treated with 25 and 50 µM GKI-1. We found that cells 
treated with GKI-1 were highly sensitive to fluorescent 
light in the blue to green spectrum, which limited our 
analysis to differential interference contrast imaging. 
This is likely due to the photo-stimulated production 
of cytotoxic GKI-1 metabolites [40]. When compared 
to cells treated with a scrambled control siRNA (SCR), 
both siGWL and GKI-1 treatments resulted in a general 
decrease in mitotic events (Figure 5D and Supporting 
Information, Videos SV1 - SV4) with 50 µM GKI-1 
eliciting an effect comparable to siGWL treatment. It is 
noteworthy that this dose-dependent decrease in mitotic 
events mirrors the decrease in p-ENSA levels with 
increasing GKI-1 concentrations.
Furthermore, relative to SCR-treated cells, both 
siGWL and GKI-1 treatment produced a significant delay 
in mitotic progression (Figure 5E and 5F, and Supporting 
Information, Videos SV1-SV4). Cells treated with 50 µM 
GKI-1 remained in prometaphase/metaphase for two to 
six hours and exited mitosis with pronounced blebbing 
and cell death. A proportion of cells underwent successful 
cell division that often resulted in unevenly sized daughter 
cells. GWL depletion resulted in a similar mitotic delay 
but caused a more pronounced failure of cytokinesis as has 
been previously observed [17] (Figure 5G and Supporting 
Information, Video SV4).
DISCUSSION
Our study describes a biochemical workflow that 
was successfully utilised to enable the facile discovery 
of a small-molecule inhibitor of human GWL. Through 
creation of a functional, minimal kinase domain expression 
construct (hGWL-KinDom) that is readily expressed in 
E.coli, we produced sufficient amounts of recombinant 
protein in order to support both inhibitor screening and 
structure-based drug discovery efforts. Whilst some false-
positives arose from screens with hGWL-KinDom - due 
to its expanded ATP-binding pocket, generated as a direct 
consequence of NCMR deletion - they were identified, and 
thus eliminated in a secondary, confirmatory screen using 
immunoprecipitated full-length hGWL.
It is noteworthy that replacing the ~500 residues of 
the NCMR, with a 4 amino acid AGC-kinase activation 
segment motif, resulted in a fully active kinase that was 
capable of phosphorylating its bona fide substrate in vitro. 
This indicates that the NCMR does not have an essential 
role in GWL kinase activity, and leaves the question open 
as to what the biological role of this unique structural 
feature actually is.
Our structural data for hGWL-KinDom confirms 
the presence of both tail / linker and hydrophobic motif 
binding pockets (HM-pocket) in the N-terminal lobe of 
the minimal kinase domain, as originally proposed by 
the laboratories of Goldberg [18] and Castro [24]. It also 
reveals the precise molecular details for the interactions 
made by the amino acids of the C-lobe anchor (CLA) and 
tether (CLT) regions, back to the main body of the kinase 
domain (Figure 2C). 
As previously indicated, whilst the C-terminal 
extension of GWL is of sufficient length for the cluster 
of phosphorylation sites at the AST (pThr873, pSer875, 
and pSer878) to potentially interact with the tail / linker 
binding site of the N-lobe, it is of an insufficient length 
for any direct interaction with the HM-pocket [18, 24]. 
Which other cellular proteins interact with the HM-pocket 
of GWL remains an important open and unanswered 
question in the field. Vigneron et al., have proposed that 
other AGC kinases, which contain a HM, directly interact 
with GWL; however, the identity of such kinases remains 
unknown. A further interesting possibility is that residues 
within the NCMR may fulfil this role, serving to stabilise 
and activate the kinase activity of GWL, without the need 
for additional protein partners. Clearly, more experimental 
work is required to address these particular points.
Until now, there has been a paucity in pharmacologic 
probes of GWL function and cellular biology. We describe 
herein the compound GKI-1, a novel ‘first generation 
inhibitor’ of human GWL that shows activity in cells 
against its intended target as judged by the observed 
reduction in ENSA phosphorylation levels. Despite the in 
vitro off-target range of GKI-1, it appears to cause cellular 
phenotypes that are surprisingly similar to the effects 
caused by GWL siRNA treatment (i.e. delayed mitotic 
entry and aberrant mitotic progression) [1, 15]. However, 
GWL depletion causes a more pronounced failure in 
cytokinesis that we only rarely observed in GKI-1 treated 
cells. This difference could be due to the incomplete 
inactivation of the kinase by the compound, or could 
point to a kinase-independent function of GWL. Cleary, 
further work will be required to precisely define on- and 
off-target effects of GKI-1 and to improve its potency and 
specificity by developing 2nd generation inhibitors based 
on this compound.
EXPERIMENTAL PROCEDURES
Full experimental procedures are provided in 
Supporting Information.
Expression constructs
hGWLFL
The mammalian expression construct for 
N-terminally FLAG-tagged full-length human GWL has 
previously been described [28].
hGWL-KinDom
A synthetic gene was purchased, codon-optimised 
for expression in E. coli - that encoded amino acids (aa) 
1-194 + ‘RTFC’ + 740-879 of hGWL; where as indicated, 
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the ‘RTFC’-linking sequence was taken from PKCα. The 
gene was subsequently sub-cloned into the expression 
vector pTHREE-E, which adds a rhinovirus 3C-protease 
cleavable GST affinity-tag to the front of the encoded 
protein. 
Expression and purification of hGWL-KinDom
Expression and purification of hGWL-KinDom 
was carried out using standard chromatographic methods, 
using Amintra Glutathione Resin [Expedeon] and a 
HiLoad 26/60 Superdex 75 size exclusion chromatography 
column [GE Healthcare]. 
Crystallisation
Crystallisation, data collection, phasing and 
refinement were performed as described in Supporting 
Information. Statistics for data collection and model 
refinement are provided in Supporting Information Table 
S1.
Thermal shift assay
Assays were performed using a modified version of 
the protocol previously described in [41]. 
Antibodies and western analysis
Polyclonal rabbit anti-GWL antibodies were 
generated and purified by Eurogentec. Mouse anti-Flag 
M2, rabbit [Prestige Antibodies] and mouse (RIPLY 
74C) anti-MASTL (GWL) antibodies were purchased 
from Sigma-Aldrich and Abcam respectively. Polyclonal 
rabbit anti-phospho(Ser67)-ENSA/ARPP19 antibody was 
generated by Generon. Secondary antibodies were HRP-
conjugated, polyclonal goat-derived antibodies against 
mouse and rabbit [Dako, Agilent Technologies].
Kinase assays
Full methods are provided in Supporting 
Information.
Inhibitor screens with hGWL-KinDom
Two small-molecule compound libraries, enriched 
with pharmacophores known to interact with the ATP-
binding site of protein kinases, were screened as a pooled 
library in a Kinase-GloMax luminescence-kinase assay. 
Synthesis of GKI-1/2
All commercial reagents were purchased from 
Sigma-Aldrich, Alfa Aesar, Apollo Scientific, or 
Fluorochem and of the highest available purity. Anhydrous 
solvents were purchased from Acros (AcroSeal) or Sigma-
Aldrich (SureSeal) and were stored under nitrogen. Proton 
nuclear magnetic resonance spectra were recorded at 500 
MHz on a Varian VNMRS 500 MHz spectrometer, at 30 
°C. Carbon Nuclear Magnetic Resonance spectra were 
recorded at 125 MHz on a Varian 500 MHz spectrometer. 
LCMS data were recorded on a Waters 2695 HPLC using 
a Waters 2487 UV detector and a Thermo LCQ ESI-MS. 
Samples were eluted through a Phenomenex Lunar 3μ C18 
50 mm × 4.6 mm column, using water and acetonitrile 
acidified with 0.1% formic acid at 1 ml/min and detected 
at 254 nm. The gradient employed was a 10 min. method 
of 5-95% MeCN. Mass Spectra (HRMS) were recorded 
at the University of Sussex Mass Spectrometry Centre on 
a high-resolution Orbitrap-XL instrument (Thermofisher). 
All experiments were carried out under an inert 
atmosphere of N2 unless otherwise stated.
Synthesis of 4-(3-bromophenyl)-1-(oxan-2-yl)-1H-
pyrazole (1A)
A solution of 4-(3-bromophenyl)-1H-pyrazole 
(1000 mg, 4.48 mmol) in toluene (30 mL) was treated 
with 3,4-dihydro-2H-pyran (0.49 mL, 5.38 mmol) and a 
few drops of trifluoroacetic acid (0.03 mL, 0.45mmol). 
The reaction mixture was heated to 100°C for 6 hours 
then cooled to room temperature and washed with 
saturated sodium bicarbonate solution, dried (MgSO4) 
and concentrated to dryness under reduced pressure. The 
crude was purified by flash chromatography eluting with 
a gradient of petroleum ether: EtOAc (0 to 30% EtOAc). 
The desired fractions were evaporated to dryness in vacuo 
to afford the product as a white solid (1370 mg, 98% 
yield). 1H NMR (500 MHz, DMSO-d6) δ 8.43 (s, 1H), 
7.99 (s, 1H), 7.84 (s, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.36 
(d, J = 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 5.38 (dd, J 
= 10.0, 2.3 Hz, 1H), 3.96 - 3.85 (m, 1H), 3.68 - 3.55 (m, 
1H), 2.16 - 2.02 (m, 1H), 1.99 - 1.88 (m, 2H), 1.75 - 1.60 
(m, 1H), 1.57 - 1.46 (m, 2H).
Synthesis of N-(4-chlorophenyl)-3-[1-(oxan-2-yl)-
1H-pyrazol-4-yl]aniline (THP-GKI-1)
A mixture of 4-(3-bromophenyl)-1-(oxan-2-yl)-
1H-pyrazole (1300 mg, 4.23 mmol), 4-chloroaniline 
(0.57 mL, 5.08 mmol), tris(dibenzylideneacetone)
dipalladium(0) (78.67 mg, 0.09 mmol), XPhos (161.2 mg, 
0.34 mmol) and sodium tert-butoxide (569.39 mg, 5.92 
mmol) in toluene (25 mL) was purged with nitrogen and 
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heated to 100°C for 3 hours. The reaction mixture was 
cooled to room temperature and washed with water and 
brine, dried (MgSO4) and concentrated to dryness under 
reduced pressure. The crude was purified by flash column 
chromatography eluting with a gradient of petroleum 
ether: EtOAc (0 to 30%). The desired fractions were 
concentrated to dryness in vacuo to afford the product as 
a white solid (1459 mg, 92% yield). 1H NMR (500 MHz, 
DMSO-d6) δ 8.26 (s, 1H), 8.24 (s, 1H), 7.83 (s, 1H), 7.28 
- 7.17 (m, 4H), 7.12 - 7.01 (m, 3H), 6.89 (d, J = 8.1 Hz, 
1H), 5.38 (dd, J = 10.0, 2.3 Hz, 1H), 3.96 - 3.88 (m, 1H), 
3.66 - 3.54 (m,1H), 2.17 - 2.02 (m, 1H), 1.98 - 1.84 (m, 
2H), 1.74 - 1.59 (m, 1H), 1.57 - 1.46 (m, 2H).
Synthesis of N-(4-chlorophenyl)-3-(1H-pyrazol-4-
yl)aniline (GKI-1)
A solution of N-(4-chlorophenyl)-3-[1-(oxan-2-
yl)-1H-pyrazol-4-yl]aniline (1550 mg, 4.38 mmol) in 
methyl alcohol (30 mL) was treated with concentrated 
hydrochloric acid (1.99 mL, 21.9 mmol) and the reaction 
mixture stirred at room temperature for 3 hours. The 
reaction mixture was neutralised with aqueous 1M NaOH 
solution and the precipitate filtered under suction and 
washed with water. The solid was then re-dissolved in 
EtOAc, washed with brine, dried (MgSO4) and solvent 
evaporated to dryness under reduced pressure. The crude 
was triturated with hot dichloromethane and dried under 
high vacuum to afford the product as a white solid (625 
mg, 52% yield). 1H NMR (500 MHz, DMSO-d6) δ 12.89 
(s, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 7.82 (s, 1H), 7.29 - 7.16 
(m, 4H), 7.13 - 6.99 (m, 4H), 6.89 (d, J = 7.9 Hz, 1H); 13C 
NMR (125Mhz, DMSO-d6) δ 143.7, 143.2, 134.4, 130.1, 
129.0, 125.8, 123, 121.8, 118.2, 115.6, 114.8; LCMS-
LCQ: 10 mins, 5-95% MeCN, Rt = 6.63, > 99% purity; 
[M+H]+ 270.20; HRMS (ESI) calculated for C15H12ClN3 
(M + H+) 270.0790, found 270.0793.
Synthesis of 4-(4-bromophenyl)-1-(oxan-2-yl)-1H 
pyrazole (1B)
A solution of 4-(4-bromophenyl)-1H-pyrazole 
(2150 mg, 9.64 mmol) in toluene (50 mL) was treated 
with 3,4-dihydro-2H-pyran (0.88 mL, 9.64 mmol) and 
trifluoroacetic acid (0.07 mL, 0.96 mmol). The reaction 
mixture was heated to 100°C for 6 hours then cooled to 
room temperature and washed with saturated sodium 
bicarbonate solution, dried (MgSO4) and concentrated to 
dryness under reduced pressure. The crude was purified 
by flash chromatography eluting with a petroleum 
ether:EtOAc gradient (0 to 30% EtOAc). The desired 
fractions were concentrated to dryness in vacuo to afford 
the product as a white solid (2.97 g, 96% yield). 1H NMR 
(500 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.94 (s, 1H), 7.57 
(d, J = 8.6 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H), 5.38 (dd, J = 
9.9, 2.4 Hz, 1H), 3.96 - 3.87 (m, 1H), 3.67- 3.56 (m, 1H), 
2.15 - 2.02 (m, 1H), 1.99 -1.86 (m, 2H), 1.74 - 1.59 (m, 
1H), 1.57 - 1.47 (m, 2H).
Synthesis of N-(4-chlorophenyl)-4-[1-(oxan-2-yl)-
1H-pyrazol-4-yl]aniline (THP-GKI-2)
A mixture of 4-(4-bromophenyl)-1-(oxan-2-yl)-1H 
pyrazole (500 mg, 1.63 mmol), 4-chloroaniline (0.22 mL, 
1.95 mmol), tris(dibenzylideneacetone)dipalladium(0) 
(30.26 mg, 0.0300 mmol), XPhos (62 mg, 0.13 mmol) 
and sodium tert-butoxide (219 mg, 2.28 mmol) in toluene 
(10 mL) was purged with nitrogen and heated to 100°C 
for 3 hours. The reaction mixture was cooled to room 
temperature and washed with water and brine. The 
organic phase was dried (MgSO4) and concentrated to 
dryness under reduced pressure. The crude was purified 
by flash column chromatography eluting with a gradient 
of petroleum ether:EtOAc (0 to 30%). The desired 
fractions were evaporated in vacuo to afford the product 
as a white solid (344 mg, 58% yield). 1H NMR (500 MHz, 
DMSO-d6) δ 8.27 (s, 1H), 8.18 (s, 1H), 7.82 (s, 1H), 7.47 
(d, J = 8.6 Hz, 2H), 7.22 (d, J = 8.9 Hz, 2H), 7.07 - 6.97 
(m, 4H), 5.37 (dd, J = 10.0, 2.3 Hz, 1H), 3.96 - 3.87 (m, 
1H), 3.68 - 3.57 (m,1H), 2.09 (d, J = 7.6 Hz, 1H), 1.96 - 
1.86 (m, 2H), 1.75 - 1.60 (m, 1H), 1.59 - 1.47 (m, 2H).
Synthesis of N-(4-chorophenyl)-4-(1H-pyrazol-4-
yl)aniline (GKI-2)
A solution of N-(4-chorophenyl)-4-[1-(oxan-2-yl)-
1H-pyrazol-4-yl]aniline (344 mg, 0.97 mmol) in ethanol 
(10 mL) was treated with concentrated hydrochloric acid 
(0.44 mL, 4.86 mmol) and the reaction mixture stirred 
for 3 hours at room temperature then cooled to room 
temperature and neutralised with 1 M aqueous sodium 
hydroxide solution. A precipitate was collected by 
filtration, washed with water and dried under suction. The 
solid was re-crystallised from hot acetonitrile to afford the 
product as a white solid (106 mg, 39% yield). 1H NMR 
(500 MHz, DMSO-d6) δ 12.80 (s, 1H), 8.23 (s, 1H), 8.03 
(s, 1H), 7.80 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.21 (d, J 
= 8.8 Hz, 2H), 7.09 - 6.94 (m, 4H); 13C NMR (125Mhz, 
DMSO-d6) δ 143.3, 141.2, 136.2, 129.4, 126.5, 125.9, 
14.9, 122.7, 121.7, 118.5, 117.9; LCMS-LCQ: 10 mins, 
5-95% MeCN, Rt = 6.51 mins, > 99% purity; [M+H]+ 
270.16; HRMS (ESI) calculated for C15H12ClN3 (M + H+) 
270.0790, found 270.0794.
Molecular docking - AutoDock
GKI-1/2 were docked into the ATP-binding site of 
the hGWL-KinDom crystal structure using AutoDock 
4.2.6. Full methods are provided in Supporting 
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Information.
Cell culture
HeLa cells were cultured in Dulbecco’s modified 
Eagle Medium (DMEM) supplemented with 10% v/v 
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/
ml streptomycin in a 37 °C, 5% CO2 incubator.
Immunofluorescence and Time-lapse video 
microscopy
HeLa cells were plated on glass coverslips and 
then transfected with siRNAs using Lipofectamine 
RNAiMax [ThermoFisher Scientific]. 48 hours after 
treatment, cells to be used for immunofluorescence were 
treated with nocodozole and DMSO, or GKI-1. After 
fixing and staining with antibodies, cells were visualised 
with a ScanR High Content Screening Station [Olympus 
Life Science]. Time-lapse videos for treated cells were 
recorded on an Olympus IX3 microscope fitted with an 
Ocra-Flash 4.0 CMOS camera [Hamatsu].
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